Top

BMC Cancer

Published in:

Open Access 01-12-2017 | Research article

Comparison of different therapeutic strategies for complete hydatidiform mole in women at least 40 years old: a retrospective cohort study

Authors: Peng Zhao, Qinqing Chen, Weiguo Lu

Published in: BMC Cancer | Issue 1/2017

Abstract

Background

There are three main therapeutic strategies, namely expectant management (dilation and curettage only), prophylactic chemotherapy and prophylactic total hysterectomy for treating older women with complete hydatidiform mole (CHM). However, the scientific community has so far, not unanimously accepted the above-mentioned methods. The objective of this study was to evaluate the effectiveness of these therapeutic strategies in preventing post-molar gestational trophoblastic neoplasia (GTN) pertaining to patients with CHM who were at least 40 years old.

Methods

Hundred and seventy-one patients from our hospital who had histologically been diagnosed of CHM and underwent treatment from January 2004 to December 2013 were included. All patients were followed continuously for a minimum of 2 years after which relevant clinical data were extracted and analysed.

Results

All patients were divided to three groups. Group 1 consisted of 124 patients, treated by expectant management, and the incidence of post-molar GTN was 37.1%. Group 2 included 12 patients who received prophylactic chemotherapy, with an incidence of 41.7%. The remaining 35 patients, Group 3, underwent prophylactic total hysterectomy, with the lowest incidence of 11.4%. A significantly lower incidence was noted in group 3 as compared to group 1 (P = 0.004). GTN patients who received prophylactic chemotherapy required, on average, longer time to be diagnosed of GTN and had higher probability of chemotherapy resistance (P = 0.031 and P = 0.024).

Conclusions

This retrospective analysis showed that prophylactic total hysterectomy was the most effective therapeutic strategy for treating CHM in women at least 40 years old of age.

Available only for authorised users

Sun SY, Melamed A, Joseph NT, Gockley AA, Goldstein DP, Bernstein MR, et al. Clinical presentation of complete Hydatidiform mole and partial Hydatidiform mole at a regional Trophoblastic disease Center in the United States over the past 2 decades. Int J Gynecol Cancer. 2016;26(2):367–70. https://doi.org/10.1097/IGC.0000000000000608.CrossRefPubMed

Curry SL, Hammond CB, Tyrey L, Creasman WT, Parker RT. Hydatidiform mole: diagnosis, management, and long-term followup of 347 patients. Obstet Gynecol. 1975;45(1):1–8.PubMed

Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003;4(11):670–8.CrossRefPubMed

Sun R, Zhang Y, Zheng W, Tian Q, An R, Xue Y. Clinical characteristics of gestational Trophoblastic Neoplasia: a 15-year hospital-based study. Int J Gynecol Cancer. 2016;26(1):216–21. https://doi.org/10.1097/IGC.0000000000000570.CrossRefPubMed

Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am. 2012;26(1):111–31. https://doi.org/10.1097/IGC.0000000000000570.CrossRefPubMed

Savage PM, Sita-Lumsden A, Dickson S, Iyer R, Everard J, Coleman R, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol. 2013;33(4):406–11. https://doi.org/10.3109/01443615.2013.771159.CrossRefPubMed

Garcia M, Romaguera RL, Gomez-Fernandez C. A hydatidiform mole in a postmenopausal woman. A case report and review of the literature. Arch Pathol Lab Med. 2004;128(9):1039–42.PubMed

Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med. 2001;46(2):110–6.PubMed

Uberti EM, Diestel MC, Guimarães FE, De Nápoli G, Schmid H. Single-dose actinomycin D: efficacy in the prophylaxis of postmolar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole. GynecolOncol. 2006;102(2):325–32.

10.

Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531–9. https://doi.org/10.1016/j.ajog.2010.06.073.CrossRefPubMed

11.

Rodriguez N, Goldstein DP, Berkowitz RS. Treating gestational trophoblastic disease. Expert Opin Pharmacother. 2010;11(18):3027–39. https://doi.org/10.1517/14656566.2010.512288.CrossRefPubMed

12.

Geng S, Feng FZ, Xiang Y, Wan XR, Zhou Y. Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high-risk hydatidiform mole. Zhonghua Fu Chan Ke Za Zhi. 2011;46(1):24–7.PubMed

13.

Kaye DK. Gestational trophoblastic disease following complete hydatidiform mole in Mulago hospital, Kampala, Uganda. Afr Health Sci. 2002;2(2):47–51.PubMedPubMedCentral

14.

Elias KM, Shoni M, Bernstein M, Goldstein DP, Berkowitz RS. Complete hydatidiform mole in women aged 40 to 49 years. J Reprod Med. 2012;57(5-6):254–8.PubMed

15.

Bahar AM, El-Ashnehi MS, Senthilselvan A. Hydatidiform mole in the elderly: hysterectomy or evacuation? Int J Gynaecol Obstet. 1989;29(3):233–8.CrossRefPubMed

16.

Elias KM, Goldstein DP, Berkowitz RS. Complete hydatidiform mole in women older than age 50. J Reprod Med. 2010;55(5-6):208–12.PubMed

17.

Giorgione V, Bergamini A, Cioffi R, Pella F, Rabaiotti E, Petrone M, et al. Role of surgery in the Management of Hydatidiform Mole in elderly patients: a single-center clinical experience. Int J Gynecol Cancer. 2017;27(3):550–3. https://doi.org/10.1097/IGC.0000000000000903.CrossRefPubMed

18.

Lertkhachonsuk R, Lertkhachonsuk AA. Outcomes of hysterectomy versus evacuation in elderly hydatidiform mole. Int J Gynecol Cancer. 2016;26(Suppl 3):539. https://doi.org/10.1097/01.IGC.0000503327.50238.5c.

19.

Ngan HY, Bender H, Benedet JL, Jones H, Montruccoli GC, Pecorelli S, et al. Gestational trophoblastic neoplasia, FIGO staging and classification. Int J Gynaecol Obstet. 2003;83(Suppl 1):175–7.CrossRefPubMed

20.

Hammond CB, Weed JC Jr, Currie JL. The role of operation in the current therapy of gestational trophoblastic disease. Am J Obstet Gynecol. 1980;136(7):844–58.CrossRefPubMed

21.

Pisal N, North C, Tidy J, Hancock B. Role of hysterectomy in management of gestational trophoblastic disease. Gynecol Oncol. 2002;87(2):190–2.CrossRefPubMed

22.

Garner EI, Chang-Lee WY, Lu KH, Goldstein DP, Berkowitz RS. Trophoblastic pulmonary embolization after hysterectomy for invasive complete mole. A case report. J Reprod Med. 1999;44(10):908–12.PubMed

23.

Stone M, Bagshawe KD. An analysis of the influences of maternal age, gestational age, contraceptive method and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy. Br J ObstetGynaecol. 1979;86:782–92.CrossRef

24.

Goldstein DP, Berkowitz RS. Prophylactic chemotherapy of complete molar pregnancy. Semin Oncol. 1995;22(2):157–60.PubMed

25.

Ngan HY, Kohorn EI, Cole LA, Kurman RJ, Kim SJ, Lurain JR, et al. Trophoblastic disease. Int J Gynaecol Obstet. 2012;119(Suppl 2):130–6.CrossRef

26.

Uberti EM, FajardoMdo C, Ferreira SV, Pereira MV, Seger RC, Moreira MA, et al. Reproductive outcome after discharge of patients with high-risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. GynecolOncol. 2009;115(3):476–81. https://doi.org/10.1016/j.ygyno.2009.09.012.

27.

Fu J, Fang F, Xie L, Chen H, He F, Wu T, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012;10 https://doi.org/10.1002/14651858.

28.

Kashimura Y, Kashimura M, Sugimori H, Tsukamoto N, Matsuyama T, Matsukuma K, et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer. 1986;58:624–9.CrossRefPubMed

29.

Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol. 1986;67:690–4.CrossRefPubMed

30.

Kim SJ, Na YJ, Jung SG, Kim CJ, Bae SN, Lee C. Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience. J Reprod Med. 2007;52(9):819–30.PubMed

31.

Sun SY, Melamed A, Goldstein DP, Bernstein MR, Horowitz NS, Moron AF, et al. Changing presentation of complete hydatidiform mole at the New England Trophoblastic disease center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia? Gynecol Oncol. 2015;138(1):46–9. https://doi.org/10.1016/j.ygyno.2015.05.002.CrossRefPubMed

32.

Garner EI, Goldstein DP, Feltmate CM, Berkowitz RS. Gestational trophoblastic disease. Clin Obstet Gynecol. 2007;50(1):112–22.CrossRefPubMed

33.

Kerkmeijer LG, Massuger LF, Ten Kate-Booij MJ, Sweep FC, Thomas CM. Earlier diagnosis and serum human chorionic gonadotropin regression in complete hydatidiform moles. Obstet Gynecol. 2009;113(2 Pt 1):326–31. https://doi.org/10.1097/AOG.0b013e3181945a4f.CrossRefPubMed

34.

Thapa K, Shrestha M, Sharma S, Pandey S. Trend of complete hydatidiform mole. JNMA J Nepal Med Assoc. 2010;49(177):10–3.PubMed

Title: Comparison of different therapeutic strategies for complete hydatidiform mole in women at least 40 years old: a retrospective cohort study
Authors: Peng Zhao
Qinqing Chen
Weiguo Lu
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-017-3749-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Ablation of epidermal RXRα in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas

Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines

miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer

Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging

Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis

Life situation and psychosocial care of adolescent and young adult (AYA) cancer patients – study protocol of a 12-month prospective longitudinal study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer